Fresenius SE & Co. KGaA

Spain-based mAbxience and tech giant HP announced a joint project focused on developing an artificial intelligence solution to support monoclonal antibody and biosimilar production. The work centers on a digital twin of the biological process intended to improve predictability, consistency, and efficiency during large-scale manufacturing, according to the companies. The tool was developed using real production data processed through neural network models and later validated in an industrial environment. It allows teams to simulate, analyze and optimize stages of cell culture operations with the goal of increasing yields and reducing variability. The companies said this first prototype has already enabled more tightly controlled manufacturing campaigns under the collaboration framework. mAbxience said the platform may support biosimilar licensees and contract development and manufacturing organization (CDMO) partners by improving development timelines and operational efficiency. “Artificial intelligence may open a lot of yet untapped potential for biomanufacturing optimization,” Timo Liebig, mAbxience chief innovation officer, said in a statement. “Through this collaboration with HP, we have successfully developed our first prototype enabling more efficient, more robust and even more tightly controlled manufacturing campaigns,” added Iván Sánchez, R&D director at mAbxience. The initiative is part of a broader strategic collaboration to apply AI across key areas of mAbxience’s operations, including productivity and quality improvements. The companies stated that the solution, designed and validated at mAbxience’s site in León, Spain, may be replicable across other facilities. In August 2022, Fresenius Kabi — an operating company of Fresenius — acquired a majority stake in mAbxience, creating a dedicated and vertically integrated biosimilars development and manufacturing platform.

MADRID, Dec. 4, 2025 /PRNewswire/ -- mAbxience, a Fresenius entity, and HP Inc., a global leader in technology, announce a new project to develop an innovative artificial intelligence (AI) solution that optimizes the production process of monoclonal antibodies and biosimilars. Continue Reading Mabxience company facilities The project represents a pioneering step in the application of AI to industrial biotechnology through the creation of a digital twin of the biological process, designed to enhance predictability, consistency, and efficiency in large-scale production."This is a clear example of technology with purpose: we use artificial intelligence not only to optimize processes but to help critical treatments reach more people, faster and better," said Sergio Martínez, Technical Lead of the project at HP. Beyond its technological innovation, this solution holds transformational potential for all of mAbxience's partners, both biosimilar licensees and CDMO clients. By integrating AI into its manufacturing operations, mAbxience aims to significantly optimize its development approach towards biologics development, enhancing operational efficiencies, and optimizing resource utilization. This advancement will strengthen the company's position as a trusted, cost-competitive global biomanufacturing partner, while helping to optimize patient access to safe, high-quality biologic medicines. "Artificial intelligence may open a lot of yet untapped potential for biomanufacturing optimization," said Timo Liebig, Chief Innovation Officer at mAbxience. "Through this collaboration with HP, we have successfully developed our first prototype enabling more efficient, more robust and even more tightly controlled manufacturing campaigns. This project demonstrates how technological innovation can directly translate into better access for patients to essential biologic therapies," commented Iván Sánchez, R&D Director at mAbxience. The development was based on real production data processed through advanced neural network models and validated in an industrial setting. The resulting tool allows mAbxience teams to simulate, analyze, and optimize distinct stages of the cell culture manufacturing process, with the ultimate goal of increasing yields while reducing process variability. This initiative marks the first project under the strategic collaboration framework between HP and mAbxience, which aims to apply AI across multiple critical areas of the company to enhance productivity, quality, and sustainability throughout its global operations. The solution, designed and validated in León, also has potential to be replicated across other mAbxience sites and processes worldwide. Photo: SOURCE mAbxience 21% more press release views with Request a Demo

mAbxience, a Fresenius entity, has entered into a collaboration with HP Inc. to develop an artificial intelligence (AI) solution aimed at making biomanufacturing more efficient and reliable. The joint project uses AI and digital-twin technology to model and optimize key steps in the production of monoclonal antibodies and biosimilars. By simulating critical cell-culture parameters and predicting process outcomes, the system is designed to support more consistent yields, faster development cycles, and better control of large-scale manufacturing environments. This is a showcase of Fresenius’ pathway in leveraging AI and digital solutions, from production and supply-chain to care delivery, improving treatment quality, and expanding access to state-of-the-art therapies. Both partners view the technology as a significant step toward more data-driven and tightly managed bioproduction. The prototype, developed with real manufacturing data and validated in an industrial setting, enables teams to test scenarios virtually before applying them on the shop floor. This initiative is the first project under a broader strategic framework between HP and mAbxience at its manufacturing facility in Leon, Spain, and has the potential to be rolled out across additional sites. It represents another milestone in advancing Fresenius’ (Bio)Pharma platform and supports the goals of #FutureFresenius. Fresenius in Spain The global healthcare company Fresenius is deeply rooted in Spain. With Quirónsalud, the country’s leading hospital operator, and Fresenius Kabi, offering essential medicines and technologies for critically and chronically ill patients, the company makes a decisive difference in the life-quality of Spanish citizens. With the majority acquisition of mAbxience in 2022, Fresenius created a dedicated and vertically integrated biosimilars development and manufacturing platform. In line with its #FutureFresenius strategy, the company is further scaling in (Bio)Pharma to deliver simplification and drive efficiencies, underscoring its commitment to offering accessible, innovative, and high-quality healthcare solutions.